Telix Pharmaceuticals has selected Cardinal Health to distribute its PET agent TLX250-CDx (Zircaix) for imaging kidney cancer in the U.S., subject to its regulatory approval.
Zircaix targets carbonic anhydrase IX (or CAIX), a protein expressed on the surface of clear cell renal cell carcinoma and several other tumor types and is administered through an intravenous injection in the arm prior to diagnostic PET imaging. In a recent phase III trial, the radiotracer was shown to be safe and effective for identifying small lesions, which could allow for earlier diagnosis of the disease.
If approved, Zircaix will be the first targeted PET agent specifically for kidney cancer to be commercially available in the U.S., the company noted.
![Pittsburgh Compound B (PiB) PET distribution volume ratio (DVR) images were projected onto fsaverage surfaces from FreeSurfer and surface smoothed, with PiB (amyloid) slope maps created using ordinary least squares regression (time as only factor) and mixed effects models for 154 participants run at each vertex (P < .01; model: longitudinal Geriatric Depression Scale score estimated by amyloid slope × time + [sex + education + age] × time). This map visualizes the results of the linear mixed-effects models (t score of the main variable, amyloid slope × time) such that regions with a greater t score (red) represent areas in which greater depressive symptoms are associated with greater amyloid accumulation (amyloid slope). Anatomical landmarks are provided: L refers to the left hemisphere, R refers to the right hemisphere, and additional labels indicate the anterior and posterior ends of the brain. Images available for republishing under Creative Commons license (CC BY 4.0 DEED, Attribution 4.0 International) and courtesy of JAMA Open Network.](https://img.auntminnie.com/files/base/smg/all/image/2024/08/PET_depression.66cf997f7e441.png?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
